Nabriva Therapeutics AG (NBRV)
(Delayed Data from NSDQ)
$2.16 USD
+0.01 (0.47%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Nabriva Therapeutics AG [NBRV]
Reports for Purchase
Showing records 1 - 20 ( 150 total )
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
XENLETA''s Safety and PK in CF Were Consistent With Historical Data; Company Future Remains Uncertain; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
3Q Recap; Nabriva to Focus on SIVEXTRO Only; Seeking Strategic Alternatives For Other Programs; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
2Q Recap; SIVEXTRO Demand Hits New High Since Nabriva Took The Helm, But Cash Is Short; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
XENLETA Embarks on New Cystic Fibrosis Indication With First Patient Enrolled in Phase 1 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
4Q Recap: Modest SIVEXTRO Growth to Continue in 2022; Still Awaiting Signs of XENLETA Traction; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
4Q21 Preliminary Financial Results and 2022 Milestones Indicative of SIVEXTRO''s Continued Growth
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
IDWeek 2021: Poster Presentation Highlights Within Our Antibiotics Coverage Space
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
Preclinical Data Reveals Potent Anti-Inflammatory Activity of XENLETA, Likely Expanding its Opportunity Set
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
Vizient Could Be Key Partner to Increase XENLETA Awareness in U.S. Hospital Setting; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
XENLETA Now Approved in Taiwan; NDA Filing Submission in China Expected in 2H21; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
2Q21 Recap: SIVEXTRO Brings Much Needed Cash, But We Now Look for Steady Growth; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
Loan Amendment and ATM Use Extend Cash Runway; Maintain Neutral While We Await Signs of SIVEXTRO Traction
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: Nabriva Therapeutics AG
Industry: Medical - Biomedical and Genetics
Positive XENLETA Data to Enable Likely China Approval; Exclusive SIVEXTRO Sales Begins; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E